News

CNBC’s Angelica Peebles talks to Alnylam CEO Yvonne Greenstreet about the new administration, what to expect in 2025 and the latest on their ATTR-Cardiomyopathy…

AbstractPurpose of Review The most common type of cardiac amyloidosis is transthyretin amyloidosis (ATTR-CM). Early forms of the disease can often go undetected.…

“The symptoms are sometimes vague and they often mimic other conditions like cancer, neuropathic conditions and heart disease,” says Dr. Keyur Shah.Abnormal…

Alnylam Pharmaceuticals, Inc., an American company at the forefront of innovation, today received the 2024 Tell Award from Ambassador Niculin Jaeger, Consul General…

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its preliminary* fourth…

ARC welcomed Jan Griffin, MD, amyloidosis cardiologist at the Medical University of South Carolina. Dr. Griffin discussed how ATTR affects the heart and explored…

BackgroundLight chain amyloidosis (AL) is a progressive and a fatal disease that primarily affects cardiac tissue. Although the current approach to anti-amyloidosis…

EMPOWER CHANGEYour Voice Matters in Building a Rare Disease Advisory CouncilJoin the coalition of rare disease patients, experts, and advocates like you to push…

DelveInsight’s “AL Amyloidosis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the AL Amyloidosis, historical…

Data presented at the 2024 American Heart Association (AHA) Scientific Sessions highlighted that early initiation and continuous use of acoramidis (Attruby;…